Forbion Capital Partners

Forbion Capital Partners is a dedicated Life Sciences venture capital firm with offices in Naarden, The Netherlands, and Munich, Germany. Forbion invests in life sciences companies, particularly in world-class drug discovery & development as well as med tech companies addressing substantial unmet medical needs. Forbion’s investment team of nine investment professionals has built an impressive performance track record since the late nineties with successful investments in Rhein Biotech, Crucell, Neutec, Glycart, Borean, Impella, Alantos, Acorda, Fovea, PanGenetics and BioVex. Current assets under management exceed EUR 400M, split between three active funds and comprising some 27 promising portfolio companies. Forbion Capital Partners Fund II is supported by the European Investment Fund through its ERP and LfA facilities. Finally, Forbion co-manages Biogeneration Ventures, an early stage fund focused on (academic) spin-outs and seed investments in the Netherlands. For more information, please visit www.forbion.com

Crédit Agricole Private Equity

Crédit Agricole Private Equity is an AMF-accredited asset-management subsidiary of Crédit Agricole, specializing in direct private-equity investment in non-listed companies. A multi-specialist player, Crédit Agricole Private Equity’s team of 100 professionals manages €3.3 billion with specific expertise in LBO & Expansion, Venture Capital, Mezzanine, Co-Investment, Renewable Energy and PPP Infrastructure. The 11-strong venture capital team manages €470 million through FCPIs invested in young companies with high growth potential in 2 sectors: information technology and life sciences. Crédit Agricole Private Equity has signed up to the United Nations’ Principles for Responsible Investment (PRI).

Vesalius Biocapital

Vesalius BioCapital Partners invests in companies active in human health through venture capital funds raised since 2007. Vesalius Biocapital offers venture capital to young European innovative life science companies and has contributed to developing eleven companies since inception, one of which was acquired through a trade sale. With over € 140 million under management in two funds, Vesalius Biocapital Partners plays the role of lead investor in the large majority of its financing rounds.

LRM NV

LRM is a profit driven investment company offering entrepreneurs a unique mix of risk capital and real estate. LRM is a generalist fund that has developed specific expertise in the field of ICT, Life Sciences and Clean Tech. LRM’s activities support the economic development and overall employment in the province of Limburg. LRM focuses on various sectors and companies, from start-ups, SME’s to larger enterprises.

LRM’s activities are focused on five domains: ICT & Media, Life Sciences, Cleantech & Energy, SME’s and large enterprises. The Life Sciences franchise is managed by Nico Vandervelpen and Kris Motmans.

PMV/Vinnof

PMV is the investment company for Flanders. It gives leverage to companies that are important to the Flemish region and stimulates durable economic growth. Participatie Maatschappij Vlaanderen (PMV) is a holding company that gives shape to Flemish economic policy. It aims for financial return on its investments, with a strong awareness of its overall social responsibility. In doing so, the company guarantees sound principles of good governance and keeps a watchful eye on public interests. PMV is the driving force behind business projects that are important for the region of Flanders. It also offers leverage for innovative entrepreneurs and a new generation of investors, adding value to the money that Flanders invests in its future.

Life Science Research Partners VZW

Life Sciences Research Partners is a non-profit organization that supports financially early stage innovative companies and start-ups with a major focus in Life Sciences and is based in Leuven (Belgium). LRSP vzw has invested in Cardio3 BioSciences, Formac, Beta Cell, BioTra, Promethera and recently in Bone Therapeutics.

Devgen NV

Devgen's mission is to enable farmers to sustainably grow more food on less land, with less water, agrochemicals and labor. Devgen uses advanced biotechnology and molecular breeding technology to make high yielding seeds and crop protection solutions with a superior environmental profile.

Devgen brings this technology to the market in the world's major food and feed crops through two complementary strategies: Licensing Devgen technology for use in corn, cotton and soy and selected other crops in exchange for R&D funding, and milestone and royalty payments; producing and selling its premium hybrid seeds in major field crops such as rice, sunflower, sorghum, and pearl millet, in the Indian subcontinent and South-East Asia. In its Crop Protection unit, Devgen developed and has taken to market a novel nematicide, an agro-chemical product that protects crops from damage by parasitic nematodes.  Incorporated in 1997, Devgen has offices in Ghent (Belgium), Singapore, Hyderabad (India), General Santos (The Philippines) and Delaware (US) and employs more than 250 people.